Lugano, Switzerland, October 6, 2014 – Helsinn Group, the company focused on building quality cancer care, today announces that Helsinn Advanced Synthesis will be exhibiting at the 2014 CPHI Worldwide trade show, which will be held in France at the Paris Nord Villepinte exhibition center, from October 7th-9th 2014.
CPHI Worldwide, organized by UBM Live, is the market leading trade show for the global pharmaceutical ingredients industry and a key networking event. Last year’s event, in Frankfurt, had 34,000 attendees and 2,200 exhibitors where it hosted senior decision makers and key players from over 140 countries, covering each stage of the pharmaceutical supply chain, from drug discovery to finished dosage.
At this year’s event, Helsinn’s booth 5N99, in Hall 5, will be part of “Piazza Ticino”, a zone completely dedicated to Tessin, featuring companies from Farma Industria Ticino, and its chemical and pharmaceutical industry associates.
Farma Industria Ticino, the association of chemical and pharmaceutical industries in the Swiss canton of Ticino, includes 27 member companies with a combined workforce of 2,400 employees and which generates a total annual turnover of approximately 2 billion Swiss Francs.
Helsinn’s booth, with its new corporate brand identity, will feature its products and services, including Helsinn’s recent cytotoxic facility, and introduce its newly launched corporate brand identity. There will also be a Licensing-Out corner, highlighting the finished drug forms currently available on the market, as well as the pipeline of products under development and open for licensing discussions. This aims to demonstrate how the high manufacturing skills and capacity actually translate into top quality finished products available for healthcare professionals and patients.
Helsinn’s Chief Executive Officer, Mr. Riccardo Braglia, commented: “CPHI Worldwide is the must-attend event for the pharmaceuticals ingredients industry, and Helsinn is delighted to have the opportunity to showcase its products and services and to meet senior decision-makers from around the world at this event. We look forward to meeting you there.”
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the U.S. and a Representative Office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientificmanagement services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn’s products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at www.helsinn.com
About the CPHI
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, China, India, Japan, Southeast Asia, Russia and South America co-located with ICSE for contract services, P-MEC for machinery, equipment & technology, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com and hosts a global community with news and analysis at PharmaEvolution.com.
For more information visit: www.cphi.com
For more information, please contact:
Head of Communication & Press Office
Tel: +41 91-985-21-21
For media/external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Melissa Jumbo
Tel: +44 (0)203 709 5700